Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone versus losartan for mild to moderate essential hypertension
ChiCTR1900028244Phase 3Recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eplerenone in essential hypertension (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: Blood pressure. Started Dec 2019; status: recruiting.
02
Drugs
eplerenone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR1900028244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028244.